AI empowerment + patent expirations concentrated, 2026 will be an exciting year for healthcare private equity!

After experiencing multiple uncertainties in policy, interest rates, and regulation, the US healthcare private equity market is standing at a critical turning point.

According to Chasing Wind Trading Desk, UBS pointed out in its latest release that with the macro environment gradually clarifying, the accelerated implementation of AI technology, and the looming pressure from concentrated drug patent expirations (LOE) in the next few years, 2026 is expected to become an important year for renewed activity in the healthcare private equity and venture capital markets, as well as for improved exit pathways.

From "Suppression" to "Recovery": Market Sentiment is Warming Up

Looking back at 2025, the healthcare sector was generally under pressure in both public and private markets. Drug price reform, adjustments to medical insurance policies, uncertainty in FDA approvals, and high interest rate environments together suppressed risk appetite, and most sub-sectors underperformed the index.

UBS says, however, signs of recovery began to appear in the second half of 2025:

IPO window is loosening: In Q4 2025, Medtronic's subsidiary MDLN completed an IPO of about $7.2 billion, becoming the largest public offering of the year and sending out a key sentiment signal;The secondary market rebounded first: The biotech index XBI rebounded by nearly 50% in H2 2025, laying the foundation for the recovery of primary and private valuations;Private capital continues to flow in: VC investment in healthcare grew by 13% year-on-year in 2025, with bio-pharma related financing up about 20% year-on-year, showing long-term capital hasn't exited the market.

UBS believes that if interest rates continue to stabilize and policy uncertainty is gradually digested, this recovery momentum can be expected to carry over into 2026.

Patent Expiry (LOE) Looms, Strategic M&A Logic Reinforced

One of the structural variables driving the recovery of private healthcare in 2026 is the pressure of concentrated patent expirations faced by large pharmaceutical companies in the coming years.

UBS estimates that 2026–2033 will be a period of intensive LOE releases in the pharmaceutical industry. Against this backdrop, multinational pharma companies’ reliance on external innovation will increase significantly, directly driving up demand for strategic M&A of high-quality private biotech assets.

This trend was already showing signs in 2025:

The total value of private biotech company M&As reached $16.4 billion, up about 150% year-on-year; compared to IPOs, M&As have become the main exit route, also providing PE funds with more predictable liquidity expectations.

UBS judges that as the patent cliff approaches, competitive M&As centering on “differentiated mechanisms (MoA) + mid-late clinical assets” may further heat up in 2026.

Three Major Therapeutic Areas: Potential Main Battlefield for Private Capital

In terms of therapeutic areas, UBS highlights three main lines that may act as “catalysts” in 2026:

First, psychedelic drugs are entering a crucial validation period. Results from multiple Phase III clinical trials will be intensively revealed in 2026. UBS believes that the mechanism risks in this field are largely mitigated, so the ability to commercialize will become key to valuation differentiation — making it more suitable for defensive capital allocation.

Second, the KRAS target may embrace "paradigm validation." If RVMD's Phase III data for pancreatic cancer are positive, the market's perception of the commercial potential of the KRAS pathway could be reshaped, prompting a round of private company valuation reassessments.

Third, weight loss and metabolic diseases remain M&A hotbeds. With new oral GLP-1s and long-acting weight loss drugs moving forward, UBS expects to see continued M&A deals in 2026 around pharmacokinetics and new mechanisms.

AI is No Longer Just a "Story," But a Tool for Costs and Efficiency

Unlike before, AI’s role in healthcare is shifting from “concept-driven valuation” to “directly impacting cost structures.”

In the healthcare IT and managed care sectors, UBS particularly notes two changes:

Competition for AI medical scribe solutions intensifies: Against hospital budget pressures, automated coding and documentation tools are seen as breakthroughs in efficiency. Some systems have already observed an 11%–14% improvement in clinical workload metrics (wRVU), though they may also put reverse pressure on Medicare payment systems;Tech giants entering the field and changing industry structure: Anthropic, OpenAI, Nvidia, and other tech leaders are quickly advancing medical AI applications, combined with rapidly increasing adoption rates among physicians, pushing industry-level tech diffusion much faster than the overall economy.

UBS sees this stage of AI as more beneficial for private equity and growth assets, rather than forming a unified valuation premium in the secondary market in the short term.

PE & VC: Exit Recovery is the "Core Variable" of 2026

From the capital side, in 2025 healthcare VC investments showed a structure of “flat early-stage, rebounding late-stage,” while PE-backed exit activity rose significantly:

M&A dominated exits, IPOs remain in early-stage recovery; multiple healthcare unicorns completed listings or M&A in 2025, giving reference points for private asset pricing.

UBS judges that if there is no major shock in the macro environment, both the quantity and quality of healthcare IPOs in 2026 are likely to see marginal improvement, which in turn will enhance risk appetite in the primary and private markets.

UBS does not depict 2026 as a year of comprehensive boom for healthcare. Instead, its core view is: this is a year of "distinct differentiation and abundant structural opportunities."

The efficiency revolution brought by AI, the M&A demand driven by patent expiries, and the marginal recovery of exit channels together form the three main lines for healthcare private equity. For capital able to make precise choices across technology, clinical, and commercialization, 2026 may indeed be a year worthy of renewed excitement.

~~~~~~~~~~~~~~~~~~~~~~~~

The wonderful content above comes from Chasing Wind Trading Desk.

For more in-depth analysis, including real-time interpretation and frontline research, please join [Chasing Wind Trading Desk ▪ Annual Membership]

Risk Warning and DisclaimerThe market carries risks, and investments should be made cautiously. This article does not constitute personal investment advice, nor does it take into account each user’s specific investment objectives, financial situation, or needs. Users should consider whether any opinions, views or conclusions in this article are suited to their own specific circumstances. Investment decisions made according to this article are at your own risk.